[Quorum] CINC280A2201: A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease
The purpose of this study is to evaluate the efficacy of the study drug, INC280, in patients with advanced EGFR wild-type Non-Small Cell Lung Cancer.
Non-Small Cell Lung Cancer
≥ 18 years of age
Non-small cell lung cancer, Stage IIIB or IV
Previously treated with one or two prior lines of systemic therapy for advanced/metastatic disease or must not have received any systemic therapy for advanced/metastatic disease
Must not have been treated with crizotinib
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.
OHSU Knight Cancer Institute Information line 503-494-1080